Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,309
  • Shares Outstanding, K 15,712
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,880 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.17
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.26 +68.49%
on 03/16/20
5.09 -58.35%
on 03/03/20
-1.78 (-45.64%)
since 02/27/20
3-Month
1.26 +68.49%
on 03/16/20
5.49 -61.38%
on 01/13/20
-1.79 (-45.71%)
since 12/27/19

Most Recent Stories

More News
WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company, announces it has entered into a development agreement (the "Agreement") with CNS Pharmaceuticals,...

WBIO.CN : 0.740 (-2.63%)
CNSP : 2.12 (-11.30%)
MBRX : 0.6295 (+1.53%)
Biotechs and Big Pharma in a Race Against Time Battling Global Health Crisis

In the months since the global public health crisis rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic. The...

CNSP : 2.12 (-11.30%)
WBIO.CN : 0.740 (-2.63%)
SRNE : 1.8100 (-3.21%)
MRNA : 30.05 (+7.55%)
GILD : 72.85 (-1.37%)
INO : 8.32 (+16.36%)
CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company primarily specializing in the development of novel treatments for cancers of the brain and central nervous...

CNSP : 2.12 (-11.30%)
WBIO.CN : 0.740 (-2.63%)
CNS Pharmaceuticals Announces Business Highlights and 2019 Fourth Quarter Financial Results

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central...

CNSP : 2.12 (-11.30%)
Cns Pharmaceuticals Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Cns Pharmaceuticals Inc (NASDAQ:CNSP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 4:30...

CNSP : 2.12 (-11.30%)
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central...

CNSP : 2.12 (-11.30%)
WPD Pharmaceuticals' Brain Cancer Drug Received Positive FDA Pre-IND Guidance

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company, is pleased to provide an update that through its license partner, CNS Pharmaceuticals,...

WBIO.CN : 0.740 (-2.63%)
CNSP : 2.12 (-11.30%)
Prognosis for Treatment of Glioblastoma Multiforme Expected to Impact Market Growth for Drug Makers

The global Glioblastoma multiforme (GBM) drugs market, is projected to reach nearly $1.4 billion by 2025, expanding at a CAGR of 12.6% during the forecast period, driven by rising geriatric population,...

CNSP : 2.12 (-11.30%)
CODX : 9.15 (-2.66%)
APDN : 4.34 (+2.60%)
TNXP : 0.7300 (+1.39%)
GNPX : 2.57 (-3.02%)
Research Studies Progressing Towards New FDA Approved Treatments for Glioblastoma

Although there is presently no cure for glioblastoma, researchers are continually inching closer to new and effective treatment options. Glioblastoma is a type of brain cancer that affects the astrocytes,...

CNSP : 2.12 (-11.30%)
KPTI : 19.58 (-7.77%)
CPHI : 0.6259 (+3.45%)
TRIL : 3.99 (+1.01%)
HTBX : 0.5839 (+1.53%)
CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central...

CNSP : 2.12 (-11.30%)
Trade CNSP with:

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

2nd Resistance Point 2.49
1st Resistance Point 2.31
Last Price 2.12
1st Support Level 1.97
2nd Support Level 1.81

See More

52-Week High 5.69
Fibonacci 61.8% 4.00
Fibonacci 50% 3.47
Fibonacci 38.2% 2.95
Last Price 2.12
52-Week Low 1.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar